Voya Analysts Trim Targets as Options Turn Bullish Before November Print
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
VOYA closes Thursday at $98.39, roughly flat on the week while closest peers CRBG, EQH, and CASS each fell between 0.8% and 6.9%. That underperformance against the peer group is the sharpest immediate fact heading into the November 2 earnings release.
Options traders are not positioned defensively. The put/call ratio has collapsed to 0.22, roughly 1.4 standard deviations below its 20-day average of 0.29. That is near the lower end of the past year's range (52-week low: 0.10; high: 1.70), and the sustained drift lower over October marks a deliberate shift toward calls rather than protective puts. The lending market tells the same relaxed story: availability is vast at 3,839%, meaning there are nearly 39 shares available to borrow for every one already short. Borrowing costs have eased 26% week-on-week to 0.35%. Short interest itself, at 3.8% of the free float, has risen roughly 44% over the past month in share terms, yet the absolute level remains modest and borrow conditions offer no friction for anyone who wants to add to that position.
The analyst community has grown more cautious in the weeks before the print. JP Morgan trimmed its target from $109 to $105 on October 15, maintaining Neutral. Keefe, Bruyette & Woods went further on October 9, cutting its rating to Market Perform from Outperform and reducing its target to $108. Wells Fargo also lowered its target to $102. Against those moves, Barclays raised its target to $109 and UBS went to $127, keeping Buy. The consensus sits at a mean target of $107.83, around 10% above the current price. The split reflects a genuine disagreement. The bull case rests on capital-light fee income, 90%-plus free cash flow conversion, active buybacks ($150 million in the first quarter), and a potential re-rating of the Stop Loss business. The bear case centres on that same Stop Loss unit, execution risk around the 2023 Benefitfocus acquisition, and a valuation that, at roughly 9 times forward earnings, already prices in some of the improvement management has been signalling. The trailing P/E has expanded about 0.26 turns over the past 30 days, so the market has been giving Voya modest credit.
Insider activity over the 90 days to October 26 nets to a sale of around 37,700 shares worth roughly $3.7 million. The largest transactions were a pair of open-market sales by Santhosh Keshavan in August, each around $1.75 million and both executed under pre-arranged 10b5-1 plans. Planned sales carry less signal than discretionary ones, but the absence of any open-market buying from senior officers is worth noting. On the institutional side, T. Rowe Price added 631,723 shares in the quarter to September 30, bringing its stake to 7.5% of shares. Wellington Management and FMR both reduced exposure, with Wellington's 13G/A showing the stake trimmed from 6.6% to 4.3% as last disclosed in August.
The November 2 print will test whether Voya can deliver on the organic growth and earnings trajectory that justifies a re-rating toward peers, at a moment when the Street is trimming targets even as options traders position for the upside.
Stocks in this article
See the live data behind this article on ORTEX.
Open VOYA on ORTEX →How this article was generated
- Generated
- 30 Oct 2026, 04:34
- Data as of
- 30 Oct 2026, 04:03
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt Data
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.